A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC) Meeting Abstract
| Authors: | Beeram, M.; Krop, I.; Modi, S.; Tolcher, A.; Rabbee, N.; Girish, S.; Tibbitts, J.; Holden, S.; Lutzker, S.; Burris, H. |
| Abstract Title: | A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC) |
| Meeting Title: | 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 25 |
| Issue: | 18 Suppl. |
| Meeting Dates: | 2007 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2007-06-20 |
| Start Page: | 42s |
| Language: | English |
| ACCESSION: | WOS:000455043700181 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2007.25.18_suppl.1042 |
| Notes: | Meeting Abstract: 1042 -- Source: Wos |
